Health Gains and Financial Protection from Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from an Extended Cost-Effectiveness Analysis

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Johansson, Kjell Arne ^a   Memirie, Solomon Tessema ^a   Pecenka, Clint ^b   Jamison, Dean T ^c   Verguet, Stéphane ^d  

^a UNIVERSITY OF BERGEN   (Norway)

^b PATH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CHILD; CHILD HEALTH CARE; CHILDHOOD MORTALITY; COST CONTROL; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; ETHIOPIA; EXTENDED COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH PROGRAM; HOUSEHOLD; HUMAN; NEWBORN; NEWBORN CARE; PNEUMOCOCCAL INFECTION; PNEUMONIA; POPULATION SIZE; POVERTY; PROTECTION; SOCIAL STATUS; COST BENEFIT ANALYSIS; ECONOMICS; FINANCIAL MANAGEMENT; INCOME; INFANT; PRESCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; ETHIOPIA; FINANCING, GOVERNMENT; HEALTH CARE COSTS; HUMANS; INCOME; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POVERTY; STREPTOCOCCUS PNEUMONIAE;

EID: 84956598776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142691     Document Type: Article

References (54)

1. UN Inter-Agency Group for Child Mortality Estimation (2013) Levels & Trends in Child Mortality: Report 2013.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128. doi: 10.1016/S0140-6736(12)61728-0 PMID: 23245604
3. Institute for Health Metrics and Evaluation (2014) Global Burden of Disease study 2010. Seattle.
4. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. (2013) Global burden of childhood pneumonia and diarrhoea. Lancet 381: 1405-1416. doi: 10.1016/S0140-6736(13)60222-6 PMID: 23582727
5. World Bank, World Development Indicators (2014): The World Bank: Washington, DC.
6. Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. (2013) Global health 2035: a world converging within a generation. Lancet The Lancet Commission on Investing in Health: 1-58.
7. Wikler D, Brock D (2007) Population-level bioethics: mapping a new agenda. In: Dawson A, Verweij M, editors. Ethics, prevention and public health. Oxford: Clarendon Press Oxford University Press. pp. 78-94.
8. Brock DW (2003) Separate spheres and indirect benefits. Cost Eff Resour Alloc 1: 4. PMID: 12773217
9. Norheim OF (2010) Gini Impact Analysis: Measuring Pure Health Inequity before and after Interventions. Public Health Ethics August.
10. Johansson KA, Norheim OF (2011) Problems with prioritization: exploring ethical solutions to inequalities in HIV care. Am J Bioeth 11: 32-40.
11. Johri M, Norheim OF (2012) Can cost-effectiveness analysis integrate concerns for equity? Systematic review. Int J Technol Assess Health Care 28: 125-132. doi: 10.1017/S0266462312000050 PMID: 22494637
12. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al, editors (2006) Disease Control Priorities in Developing Countries ( 2nd Edition): Oxford University Press and The World Bank.
13. Brock D, Wikler D (2006) Ethical Issues in Resource Allocation, Research, and New Product Development. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M et al., editors. Disease Control Priorities in Developing Countries ( 2nd Edition). Washington, DC: Oxford University Press and The World Bank. pp. 259-270.
14. Daniels N (2008) Just health. Boston, Mass.: Cambridge University Press.
15. Verguet S, Laxminarayan R, Jamison D (2015) Universal public finance of turberculosis treatment in India: an extended cost-effectiveness analysis. Health Economics 24(3):318-322. doi: 10.1002/hec. 3019 PMID: 24497185
16. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. (2013) Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine 31: 4902-4910. doi: 10.1016/j.vaccine.2013.07.014 PMID: 23871824
17. Verguet S, Olson ZD, Babigumira JB, Desalegn D, Johansson KA, Kruk ME, et al. (2015) Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. Lancet Glob Health 3: e288-296. doi: 10.1016/S2214-109X(14) 70346-8 PMID: 25889470
18. Verguet S, Gauvreau CL, Mishra S, MacLennan M, Murphy SM, Brouwer ED, et al. (2015) The consequences of tobacco tax on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis. Lancet Glob Health 3: e206-216. doi: 10.1016/S2214-109X(15) 70095-1 PMID: 25772692
19. Rheingans R, Atherly D, Anderson J (2012) Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness. Vaccine 30 Suppl 1: A15-23. doi: 10.1016/j.vaccine.2012.01.018 PMID: 22520124
20. United Nations Development Programme (UNDP) (2013) Human Development Report 2013: The Rise of the South: Human Progress in a Diverse World.
21. Central Statistical Agency [Ethiopia], ICF International (2011) Ethiopia Demographic and Health Survey. Addis Ababa, Ethiopia and Calverton, Maryland, USA: Central Statistical Agency and ICF International.
22. GAVI alliance, Available: http://www.gavialliance.org/support/nvs/pneumococcal/, Accessed 8 April 2015.
23. Kim SY, Lee G, Goldie SJ (2010) Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infect Dis 10: 260. doi: 10.1186/1471-2334-10-260 PMID: 20815900
24. Ministry of Health Ethiopia (2010) Health Sector Development Program IV 2010/11-2014/15.
25. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. (2012) Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379: 2151-2161. doi: 10.1016/S0140-6736(12)60560-1 PMID: 22579125
26. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. (2013) Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 3: 010401. doi: 10.7189/jogh.03.010401 PMID: 23826505
27. Henrichsen J (1995) Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 33: 2759-2762. PMID: 8567920
28. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902. doi: 10.1016/S0140-6736(09)61204-6 PMID: 19748398
29. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987. doi: 10.1016/S0140-6736(10)60549-1 PMID: 20466419
30. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. (2010) Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 7.
31. Theodoratou E, Johnson S, Jhass A, Madhi SA, Clark A, Boschi-Pinto C, et al. (2010) The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. Int J Epidemiol 39 Suppl 1: i172-185.
32. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365: 1139-1146. PMID: 15794968
33. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360: 244-256. doi: 10.1056/NEJMoa0800836 PMID: 19144940
34. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. (2000) Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 19: 187-195. PMID: 10749457
35. Theodoratou E, Al-Jilaihawi S, Woodward F, Ferguson J, Jhass A, Balliet M, et al. (2010) The effect of case management on childhood pneumonia mortality in developing countries. Int J Epidemiol 39 Suppl 1: i155-171.
36. World Health Organization (2014) Revised WHO classification and treatment of childhood pneumonia at health facilities.
37. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H, Group WHOCHER (2004) Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ 82: 895-903. PMID: 15654403
38. The World Bank Group, Africa Region Human Development, Ministry of Health Ethiopia (2005) A Country Status Report on Health and Poverty (In Two Volumes) Volume II: Main Report
39. Griffiths UK, Korczak VS, Ayalew D, Yigzaw A (2009) Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 27: 1426-1432. doi: 10.1016/j.vaccine.2008.12.037 PMID: 19146901
40. Advisors DGD (2013) The Advance Market Commitment for Pneumococcal Vaccines-Process and design evaluation".
41. Stack ML, Ozawa S, Bishai DM, Mirelman A, Tam Y, Niessen L, et al. (2011) Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity. Health Aff (Millwood) 30: 1021-1028.
42. Chola L, Robberstad B (2009) Estimating average inpatient and outpatient costs and childhood pneumonia and diarrhoea treatment costs in an urban health centre in Zambia. Cost Eff Resour Alloc 7 doi: 10.1186/1478-7547-7-16 PMID: 19845966
43. McClellan M, Skinner J (2006) The incidence of Medicare. Journal of Public Economics 90: 257-276.
44. Salem A, Mount T (1974) A convenient descriptive model of income distribution: the gamma density. Econometrica: Journal of the Econometric Society: 1115-1127.
45. Ayieko P, Griffiths UK, Ndiritu M, Moisi J, Mugoya IK, Kamau T, et al. (2013) Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS One 8: e67324. doi: 10.1371/journal.pone.0067324 PMID: 23826268
46. World Health Organisation (2014) Making fair choices on the path to universal health coverage.
47. Mkandawire T (2005) Targeting and Universalism in Poverty Reduction. Social Policy and Development Programme Paper Number 23.
48. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962-1973. doi: 10.1016/S0140-6736(10)62225-8 PMID: 21492929
49. Bhutta ZA, Das JK, Walker N, Rizvi A, Campbell H, Rudan I, et al. (2013) Interventions to address deaths from childhood pneumonia and diarrhoea equitably: what works and at what cost? Lancet 381: 1417-1429. doi: 10.1016/S0140-6736(13)60648-0 PMID: 23582723
50. Beutels P, Thiry N, Van Damme P (2007) Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-A review (2002-2006). Vaccine 25: 1355-1367. PMID: 17208339
51. Kim SY, Goldie SJ (2008) Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 26: 191-215. PMID: 18282015
52. International Monetary Fund (IMF) Accessed 5 April 2014. Available: http://www.imf.org/external/datamapper/index.php.
53. United Nations, Department of Economic and Social Affairs, Population Division (2013) World Fertility Data 2012 (POP/DB/Fert/Rev2012).
54. United Nations, Department of Economic and Social Affairs, Population Division (2012) World Population Prospects: The 2012 Revision, Available: http://esa.un.org/unpd/wpp/index.htm